TORONTO, June 30, 2016 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN) (“GeneNews” or the “Company”) today announced that all of the nominee directors listed in the Company’s management information circular dated May 27, 2016, were elected as directors of the Company. The vote was conducted at the Company's annual and special meeting of shareholders held on June 30, 2016. The results of the vote are set out below:
| Nominee | Votes For | Votes Withheld | Percentage of Votes For | Percentage of Votes Withheld |
| James R. Howard-Tripp | 10,836,565 | 42,766 | 99.61 | 0.39 |
| Rory Riggs | 10,860,665 | 18,666 | 99.83 | 0.17 |
| Garth MacRae | 10,855,665 | 23,666 | 99.78 | 0.22 |
| Harry Glorikian | 10,830,665 | 48,666 | 99.55 | 0.45 |
| Leslie Auld | 10,860,665 | 18,666 | 99.83 | 0.17 |
| Thomas D. Stewart, Jr. | 10,860,665 | 48,666 | 97.55 | 0.45 |
About GeneNews
GeneNews is focused on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company's lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews can be found at www.GeneNews.com.
About IDL
Richmond, Virgina-based IDL is a national clinical reference lab specializing in personalized blood-based testing to help find, understand, and address cancer risk in patient populations. IDL’s mission is to provide a comprehensive menu of traditional and advanced clinical evidence-based blood tests that aid in early cancer detection. Currently IDL offers risk assessment blood tests for the three most prevalent cancer types including lung, colon and prostate. IDL is actively in-licensing and commercializing an array of DNA, RNA, protein and autoantibody blood-based cancer diagnostic tests to address early detection of all major types of cancer.